Prospects for Pharmaceuticals: Selling our ... - Japan Society

crunchkingofprussiaBiotechnology

Dec 6, 2012 (4 years and 4 months ago)

162 views





Prospects for Pharmaceuticals:

Selling our Strengths Abroad


Jon

Mowles,

UKTI

Sector

Specialist

Japan

Society

9
th

Nov


11


Setting the scene



The

UK

is

ranked

as

the

best

performer

in

the

G
8

leading

economies

per

unit

of

R&D

spend
.



4

of

the

top

6

rated

universities

in

the

world

are

in

the

UK

viz
.

Cambridge,

University

College

London,

Imperial

College

and

Oxford
.



5

of

the

top

20

medicines

in

terms

of

global

sales

were

developed

in

the

UK
.



In

the

last

10

years

Life

Sciences

departments

within

UK

universities

have

generated

over

200

spin
-
out

companies,

now

employing

over

1
,
000

people
.



Benefits
:


The

United

Kingdom

is

a

global

centre

of

excellence

in

Life

Sciences

where
:



Innovation

is

readily

commercialised
.


People

are

highly

skilled

and

motivated
.


Government

is

supportive

and

businesses

prosper
.


High

value

given

to

R&D
.

2

3

Destination
Country

No of Projects
2006
-
2010

% of global
FDI

USA

119

11%

China

85

8%

India

65

6%

UK

61

6%

Germany

59

5.5%

Ireland

46

4%

Singapore

39

3.5%

France

38

3.5%

Russia

35

3%

Canada

30

2.8%

Destination
City

No of
Projects
2006
-
2010

Singapore

39

Shanghai

26

Beijing

14

Budapest

13

Prague

11

Mumbai

10

Tokyo

10

Dublin

10

Sao Paulo

9

Berlin

9

Hyderabad

9

Moscow

9

Pharmaceutical:

Global FDI
-

2006
-

10


Time Series: January 2006
-

December 2010

Source: fDi Markets™

4

Pharmaceutical:

UK FDI 2006
-

10

0%
5%
10%
15%
20%
Proximity to markets or customers
Skilled workforce availability
Infrastructure and logistics
IPA or Govt support
Domestic Market Growth Potential
Facilities Site or Real Estate
Industry Cluster / Critical Mass
Technology or Innovation
Universities or researchers
Attractiveness / Quality of Life
-

On average the UK is recipient of 12 Pharmaceutical
projects per annum.

-

Motives for UK investment in sector both skilled
workforce and proximity to market were cited as
primary drivers.

-

R&D accounted for 39% of Pharmaceutical investment
followed by manufacturing and sales, support &
marketing.

-

UK hubs of investment were identified in London,
Cambridge and Scotland.


TOP UK INVESTORS (2006


2010):



Quintiles; Pfizer; Nicholas Piramal India (NPIL);

Amgen; Icon; Warner Chilcott; Kendle
International; Eisai; Intercell; Novartis; Granules
India; Patheon; Clariant; Wyeth; Merck KGaA;
Glenmark Pharmaceuticals;

Teva Pharmaceutical
Industries; UCB Group; Sanofi
-
Aventis; Evotec OAI;
Bilcare

5

Destination
Country

No of Projects
2006
-
2010

% of global
FDI

USA

79

16%

UK

59

13%

China

38

8%

India

33

7%

Germany

29

6%

Singapore

23

5%

France

16

3.5%

Belgium

13

3%

Netherlands

12

3%

Ireland

12

3%

Destination
Cities

No of
Projects
2006
-
2010

Singapore

23

Shanghai

16

London

12

Boston (MA)

8

Dubai

7

Beijing

6

Bangalore

6

Dublin

6

Tokyo

6

Cambridge

6

Biopharma:

Global FDI
-

2006
-

10


Time Series: January 2006
-

December 2010

Source: fDi Markets™

6

0%
5%
10%
15%
20%
25%
30%
IPA or Govt support
Proximity to markets or customers
Universities or researchers
Skilled workforce availability
Technology or Innovation
Domestic Market Growth Potential
Facilities Site or Real Estate
Finance Incentives or Taxes or Funding
Industry Cluster / Critical Mass
Infrastructure and logistics
-

On average the UK is recipient of 12
Biotechnology projects per annum.

-

Motives for UK investment in sector


26%
surveyed cited Government support as key
driver.

-

R&D accounted for 41% of Biotechnology
investment in the UK 2006
-
2010. Sales,
marketing and support accounted for 30%.

-

UK hubs of investment were identified in
London, Cambridge and Scotland.


TOP UK INVESTORS (2006


2010):


Life Technologies (Invitrogen); Sigma
-
Aldrich; Millipore; Genzyme; Pfizer;
Magellan Biosciences; Bioanalytical Systems
(BASi); Bristol
-
Myers Squibb; Schering
-
Plough; Wyeth; Serologicals; Waters;
Eurofins Scientific; Cognia; BioMarin
Pharmaceutical; MatriCal; Fziomed;
IdentiGEN; BioGuard Components &
Technologies; MediciNova

Biopharma:

UK FDI 2006
-

10

7

7

London



Biopharmaceuticals



Decoding/transformation of DNA material



Functions of sub
-
cellular organisms



Functional genomics

Cambridge



Biopharmaceuticals



Drug discovery
-
genomics,



proteomics



bioinformatics



combinatorial chemistry



Protein/DNA sequencing/engineering



Biomaterials

Oxford



Proteomics



Genomics



Chemical libraries



Vaccines



Monoclonal antibodies

Surrey



Agricultural biotechnology



Production of reagents: cell/tissue cultures

North (Manchester, York, Liverpool, Newcastle)



Bio
-
health informatics



Genomics and Proteomics



Medical Imaging



Clinical Genetics



Bio
-
manufacturing



Agricultural/Food Sciences

Northern Ireland



Diagnostics



Agriculture



Veterinary medicine



Food Sciences



Environmental

UK BioPharma Networks

Scotland (Edinburgh, Dundee, Aberdeen)



Human and animal healthcare



Environmental biotechnology



Gene therapy



Protein engineering



Combinatorial chemistry

(Source: UKTI Sector Group, 2007)

Wales



Diagnostics


Healthcare



Biotechnology

UKTI: Conclusions

1.

Within the Life Sciences Sector, the UK is a good place to do business


2.

UK Trade & Investment is the

UK Government organisation that:



Helps overseas companies to bring high quality investment to the UK economy.



Helps UK
-
based companies access international markets to succeed in an
increasingly global economy.



Works with existing foreign investors to grow their business in the UK and
internationally.



A global network. UKTI has staff in British Embassies, High Commissions and
other diplomatic offices around the world.



UK Trade & Investment


Winner 2010: Best Trade Promotion
Organisation in the developed world



UKTI

LOOKS

TO

ADD

VALUE!

8



9





Jon

Mowles


Life

Sciences

Sector

Specialist

Investment

Directorate

-

London

UK

Trade

&

Investment

jon
.
mowles@uktispecilaist
.
com

Tel
:

+
44

(
0
)

7826

912

923


UKTI

Website
:

www
.
uktradeinvest
.
gov
.
uk